The tradeoff between startups and FAANG is often:
Startup - ship a whole app to a small number of people and hope it goes global (with vanishingly small probability)
FAANG- ship a button or two to millions or billions of people
Expected value is generally higher at FAANG
It's depressing to see so many talented people from top schools with amazing resumes go work years at FAANG, and the most they can point to having shipped are a few buttons in one minor workflow.
I mean I know FAANG can afford it, but you can't. Work at a startup!
This is one of the coolest things we've build with @NeptyneHQ - automatic research in a spreadsheet. You give it a news search query and the things you want to know and it does the rest.
https://t.co/sSq6N6MfW3
A visualization of compost bins filling + emptying in NYC. Made with @NeptyneHQ + @plotlygraphs animations. The tyne here ingests the data and creates the visualization: https://t.co/NJ1nWMGMmi
It is false to suggest—as some recently have—that our patents are being used to prevent access to SIRTURO® (bedaquiline), our medicine for MDR-TB.
In fact, we have already entered into a collaboration with the Stop TB Partnership’s Global Drug Facility (“GDF”)—the largest procurer of TB medicines—which enables them to invite potential generic suppliers and purchase generic versions of SIRTURO® 100mg. On April 5, during a World Health Organization meeting, the GDF shared its intent to launch a tender for generic versions of SIRTURO® 100mg in the third quarter of 2023: https://t.co/6m49h5g7tn
In addition, we have shipped more than 660,000 courses of SIRTURO® to 159 countries since launch. Our patents made this possible, enabling us to assist countries to scale-up their use of our medicine responsibly and sustainably and invest in multiple, critical, anti-TB efforts. For instance, in the face of rising drug resistance, we support stewardship efforts that ensure MDR-TB patients can benefit from our medicine today and in the future.
Unfortunately, the most significant barrier to treatment access for patients today is the fact that millions of patients with TB go undiagnosed every year. This is a challenge that we have invested significant resources to overcome and must all get behind if we are to achieve the global goal of ending TB.
@JNJNews it would be an excellent business, PR, and morally correct move if you let your TB drug patent expire.
And it will be reprehensible if you don't.
#PatientsNotPatents
We developed a new multivalent mRNA vaccine against all known influenza virus subtypes. Our study describing the vaccine was just published in @ScienceMagazine. 1/n
https://t.co/HxTKm47EC3